Periadventitial drug delivery for the prevention of intimal hyperplasia following open surgery

Journal of Controlled Release

Volumn 233, Issue , 2016, Pages 174-180

  Chaudhary, Mirnal A ^a   Guo, Lian Wang ^a   Shi, Xudong ^a   Chen, Guojun ^b   Gong, Shaoqin ^b   Liu, Bo ^a   Kent, K Craig ^a  

^a University of Wisconsin Health   (United States)

^b Wisconsin Electric Machines and Power Electronics Consortium   (United States)

Author keywords

Hydrogel; Intimal hyperplasia; Nanoparticles; Open surgery; Periadventitial drug delivery; Wrap

Indexed keywords

DISEASES; DRUG PRODUCTS; HYDROGELS; MEDICAL APPLICATIONS; NANOPARTICLES; POLYMERS; SURGERY; TARGETED DRUG DELIVERY;

BIORESORBABLE HYDROGELS; COMPLEMENTARY PROPERTY; DRUG DELIVERY SYSTEM; INTIMAL HYPERPLASIA; OPEN SURGERY; SUSTAINED DRUG RELEASE; VASCULAR RECONSTRUCTION; WRAP;

CONTROLLED DRUG DELIVERY;

DRUG CARRIER; NANOPARTICLE; POLYMER;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; HUMAN; HYDROGEL; HYPERPLASIA; INFLAMMATION; INJURY; INTIMAL HYPERPLASIA; MECHANICAL STRESS; NONHUMAN; PATENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIADVENTITIAL DRUG DELIVERY SYSTEM; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; VASCULAR SURGERY; VEIN GRAFT; WRAP; ADMINISTRATION AND DOSAGE; ADVENTITIA; ANIMAL; INTIMA; PATHOLOGY; POSTOPERATIVE COMPLICATION; SURGERY;

ADVENTITIA; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGELS; HYPERPLASIA; NANOPARTICLES; POSTOPERATIVE COMPLICATIONS; SURGICAL PROCEDURES, OPERATIVE; TUNICA INTIMA;

EID: 84971298063     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.05.002     Document Type: Review

References (70)

1. J. Jim, P.L. Owens, L.A. Sanchez, and B.G. Rubin Population-based analysis of inpatient vascular procedures and predicting future workload and implications for training J. Vasc. Surg. 55 2012 1394 1399 (discussion 1399-1400)
2. S. Goldman, K. Zadina, T. Moritz, T. Ovitt, G. Sethi, J.G. Copeland, L. Thottapurathu, B. Krasnicka, N. Ellis, R.J. Anderson, and W. Henderson Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study J. Am. Coll. Cardiol. 44 2004 2149 2156
3. N. Samano, H. Geijer, M. Liden, S. Fremes, L. Bodin, and D. Souza The no-touch saphenous vein for coronary artery bypass grafting maintains a patency, after 16 years, comparable to the left internal thoracic artery: a randomized trial J. Thorac. Cardiovasc. Surg. 150 2015 880 888
4. S. Kwei, G. Stavrakis, M. Takahas, G. Taylor, M.J. Folkman, M.A. Gimbrone, and G. García-Cardeña Early adaptive responses of the vascular wall during venous arterialization in mice Am. J. Pathol. 164 2004 81 89
5. G. Tepe, J. Laird, P. Schneider, M. Brodmann, P. Krishnan, A. Micari, C. Metzger, D. Scheinert, T. Zeller, D.J. Cohen, D.B. Snead, B. Alexander, M. Landini, and M.R. Jaff Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial Circulation 131 2015 495 502
6. M.D. Dake, G.M. Ansel, M.R. Jaff, T. Ohki, R.R. Saxon, H.B. Smouse, S.A. Snyder, E.E. O'Leary, G. Tepe, D. Scheinert, and T. Zeller Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies J. Am. Coll. Cardiol. 61 2013 2417 2427
7. T.F. Luscher, J. Steffel, F.R. Eberli, M. Joner, G. Nakazawa, F.C. Tanner, and R. Virmani Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications Circulation 115 2007 1051 1058
8. A. Zalewski, and Y. Shi Vascular myofibroblasts. Lessons from coronary repair and remodeling Arterioscler. Thromb. Vasc. Biol. 17 1997 417 422
9. D. Wiedemann, A. Kocher, N. Bonaros, S. Semsroth, G. Laufer, M. Grimm, and T. Schachner Perivascular administration of drugs and genes as a means of reducing vein graft failure Curr. Opin. Pharmacol. 12 2012 203 216
10. M.R. Kibbe, S. Nie, T. Yoneyama, K. Hatakeyama, A. Lizonova, I. Kovesdi, T.R. Billiar, and E. Tzeng Optimization of ex vivo inducible nitric oxide synthase gene transfer to vein grafts Surgery 126 1999 323 329
11. M.A. Lovich, L. Brown, and E.R. Edelman Drug clearance and arterial uptake after local perivascular delivery to the rat carotid artery J. Am. Coll. Cardiol. 29 1997 1645 1650
12. G. McLennan, M.S. Johnson, K.R. Stookey, Z. Zhang, and W.K. Fife Kinetics of release of heparin from alginate hydrogel J. Vasc. Interv. Radiol. 11 2000 1087 1094
13. X. Shi, G. Chen, L.W. Guo, Y. Si, M. Zhu, S. Pilla, B. Liu, S. Gong, and K.C. Kent Periadventitial application of rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosis PLoS One 9 2014 e89227
14. A. Forte, M. Grossi, K.M. Turczynska, K. Svedberg, B. Rinaldi, M. Donniacuo, A. Holm, B. Baldetorp, M. Vicchio, M. De Feo, P. Sante, U. Galderisi, L. Berrino, F. Rossi, P. Hellstrand, B.O. Nilsson, and M. Cipollaro Local inhibition of ornithine decarboxylase reduces vascular stenosis in a murine model of carotid injury Int. J. Cardiol. 168 2013 3370 3380
15. S.C. Owen, H. Li, W.G. Sanders, A.K. Cheung, and C.M. Terry Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft J. Control. Release 146 2010 23 30
16. S.M. Seedial, S. Ghosh, R.S. Saunders, P.A. Suwanabol, X. Shi, B. Liu, and K.C. Kent Local drug delivery to prevent restenosis J. Vasc. Surg. 57 2013 1403 1414
17. S. Baek, and K.L. March Gene therapy for restenosis: getting nearer the heart of the matter Circ. Res. 82 1998 295 305
18. S.S. Ahanchi, V.N. Varu, N.D. Tsihlis, J. Martinez, C.G. Pearce, M.R. Kapadia, Q. Jiang, J.E. Saavedra, L.K. Keefer, J.A. Hrabie, and M.R. Kibbe Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome Am J Physiol Heart Circ Physiol 2008 H2388 H2398
19. T.K. Hoare, and Daniel Hydrogels in drug delivery: progress and challenges Polymer 49 2008 1993 2007
20. J.J. Escobar-Chavez, M. Lopez-Cervantes, A. Naik, Y.N. Kalia, D. Quintanar-Guerrero, and A. Ganem-Quintanar Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations J. Pharm. Pharm. Sci. 9 2006 339 358
21. G.M. Zentner, R. Rathi, C. Shih, J.C. McRea, M.H. Seo, H. Oh, B.G. Rhee, J. Mestecky, Z. Moldoveanu, M. Morgan, and S. Weitman Biodegradable block copolymers for delivery of proteins and water-insoluble drugs J. Control. Release 72 2001 203 215
22. M.R. Kapadia, L.W. Chow, N.D. Tsihlis, S.S. Ahanchi, J.W. Eng, J. Murar, J. Martinez, D.A. Popowich, Q. Jiang, J.A. Hrabie, J.E. Saavedra, L.K. Keefer, J.F. Hulvat, S.I. Stupp, and M.R. Kibbe Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia J. Vasc. Surg. 47 2008 173 182
23. X. Huang, and C.S. Brazel On the importance and mechanisms of burst release in matrix-controlled drug delivery systems J. Control. Release 73 2001 121 136
24. A.C.M. dos Santos, A.C.S. Akkari, I.R.S. Ferreira, C.R. Maruyama, M. Pascoli, V.A. Guilherme, E. de Paula, L.F. Fraceto, R. de Lima, S. Melo Pda, and D.R. de Araujo Poloxamer-based binary hydrogels for delivering tramadol hydrochloride: sol-gel transition studies, dissolution-release kinetics, in vitro toxicity, and pharmacological evaluation Int. J. Nanomedicine 2015 2391 2401
25. B. Jeong, Y.H. Bae, and S.W. Kim Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers J. Control. Release 63 2000 155 163
26. O. Jeon, C. Powell, L.D. Solorio, M.D. Krebs, and E. Alsberg Affinity-based growth factor delivery using biodegradable, photocrosslinked heparin-alginate hydrogels J. Control. Release 154 2011 258 266
27. B. Reid, M. Gibson, A. Singh, J. Taube, C. Furlong, M. Murcia, and J. Elisseeff PEG hydrogel degradation and the role of the surrounding tissue environment J. Tissue Eng. Regen. Med. 9 2015 315 318
28. R. Zhu, G. Wu, X. Liu, D. Shi, B. Cao, R. Gu, J. Xiao, and H. Liao PNIPAM Hydrogel Induces Skeletal Muscle Inflammation Response RSC Adv. 5 2015 28023 28029
29. W. Zhu, T. Masaki, A.K. Cheung, and S.E. Kern In-vitro release of rapamycin from a thermosensitive polymer for the inhibition of vascular smooth muscle cell proliferation J. Bioequiv. Availab. 1 2009 3 12
30. W.G. Sanders, P.C. Hogrebe, D.W. Grainger, A.K. Cheung, and C.M. Terry A biodegradable perivascular wrap for controlled, local and directed drug delivery J. Control. Release 161 2012 81 89
31. C. Chun, S.M. Lee, S.Y. Kim, H.K. Yang, and S.C. Song Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications Biomaterials 30 2009 2349 2360
32. A.L. Kjøniksen, M.T. Calejo, K. Zhu, B. Nyström, and S.A. Sande Stabilization of pluronic gels in the presence of different polysaccharides J. Appl. Polym. Sci. 131 2015 40465
33. K.Y. Lee, and D.J. Mooney Hydrogels for tissue engineering Chem. Rev. 101 2001 1869 1879
34. X. Yu, T. Takayama, S.A. Goel, X. Shi, Y. Zhou, K.C. Kent, W.L. Murphy, and L.W. Guo A rapamycin-releasing perivascular polymeric sheath produces highly effective inhibition of intimal hyperplasia J. Control. Release 191 2014 47 53
35. W.J. Ciccone 2nd, C. Motz, C. Bentley, and J.P. Tasto Bioabsorbable implants in orthopaedics: new developments and clinical applications J. Am. Acad. Orthop. Surg. 9 2001 280 288
36. N.M. Pires, B.L. van der Hoeven, M.R. de Vries, L.M. Havekes, B.J. van Vlijmen, W.E. Hennink, P.H. Quax, and J.W. Jukema Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff Biomaterials 26 2005 5386 5394
37. I. Skalsky, O. Szarszoi, E. Filova, M. Parizek, A. Lytvynets, J. Maluskova, A. Lodererova, E. Brynda, V. Lisa, Z. Burdikova, M. Capek, J. Pirk, and L. Bacakova A perivascular system releasing sirolimus prevented intimal hyperplasia in a rabbit model in a medium-term study Int. J. Pharm. 427 2012 311 319
38. E.K. Gregory, A.R. Webb, J.M. Vercammen, M.E. Flynn, G.A. Ameer, and M.R. Kibbe Periadventitial atRA citrate-based polyester membranes reduce neointimal hyperplasia and restenosis after carotid injury in rats Am. J. Physiol. Heart Circ. Physiol. 307 2014 H1419 H1429
39. M.C. Serrano, A.K. Vavra, M. Jen, M.E. Hogg, J. Murar, J. Martinez, L.K. Keefer, G.A. Ameer, and M.R. Kibbe Poly(diol-co-citrate)s as novel elastomeric perivascular wraps for the reduction of neointimal hyperplasia Macromol. Biosci. 11 2011 700 709
40. M. Bahcivan, S. Yucel, M. Kefeli, M.K. Gol, B. Can, and H.T. Keceligil Inhibition of vein graft intimal hyperplasia by periadventitial application of hyaluronic acid-carboxymethyl cellulose: an experimental study Scand. Cardiovasc. J. 42 2008 161 165
41. W.D. Paulson, N. Kipshidze, K. Kipiani, N. Beridze, M.V. DeVita, S. Shenoy, and S.S. Iyer Safety and efficacy of local periadventitial delivery of sirolimus for improving hemodialysis graft patency: first human experience with a sirolimus-eluting collagen membrane (Coll-R) Nephrol. Dial. Transplant. 27 2012 1219 1224
42. S. Parveen, R. Misra, and S.K. Sahoo Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging Nanomedicine 8 2012 147 166
43. J. Tian, K.K. Wong, C.M. Ho, C.N. Lok, W.Y. Yu, C.M. Che, J.F. Chiu, and P.K. Tam Topical delivery of silver nanoparticles promotes wound healing ChemMedChem 2 2007 129 136
44. K.C. Bhol, and P.J. Schechter Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis Dig. Dis. Sci. 52 2007 2732 2742
45. M.V. Park, A.M. Neigh, J.P. Vermeulen, L.J. de la Fonteyne, H.W. Verharen, J.J. Briede, H. van Loveren, and W.H. de Jong The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles Biomaterials 32 2011 9810 9817
46. L. Zhang, F.X. Gu, J.M. Chan, A.Z. Wang, R.S. Langer, and O.C. Farokhzad Nanoparticles in medicine: therapeutic applications and developments Clin. Pharmacol. Ther. 83 2008 761 769
47. G. Chen, L. Wang, T. Cordie, C. Vokoun, K.W. Eliceiri, and S. Gong Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging Biomaterials 47 2015 41 50
48. C.E. Morgan, M.A. Wasserman, and M.R. Kibbe Targeted Nanotherapies for the treatment of surgical diseases Ann. Surg. 263 2016 900 907
49. M. Wang, and M. Thanou Targeting nanoparticles to cancer Pharmacol. Res. 62 2010 90 99
50. S. Hussain, A. Pluckthun, T.M. Allen, and U. Zangemeister-Wittke Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system Mol. Cancer Ther. 6 2007 3019 3027
51. R.X. Yin, D.Z. Yang, and J.Z. Wu Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis Theranostics 4 2014 175 200
52. T. Rajathurai, S.I. Rizvi, H. Lin, G.D. Angelini, A.C. Newby, and G.J. Murphy Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts Circ. Cardiovasc. Interv. 3 2010 157 165
53. J.M. Li, P.E. Newburger, M.J. Gounis, P. Dargon, X. Zhang, and L.M. Messina Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model Gene Ther. 17 2010 1279 1287
54. W.J. Gasper, C.A. Jimenez, J. Walker, M.S. Conte, K. Seward, and C.D. Owens Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation Circ. Cardiovasc. Interv. 6 2013 701 709
55. S.D. Steichen, M. Caldorera-Moore, and N.A. Peppas A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics Eur. J. Pharm. Sci. 48 2013 416 427
56. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
57. M. Prabaharan, J.J. Grailer, S. Pilla, D.A. Steeber, and S. Gong Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(l-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery Biomaterials 30 2009 3009 3019
58. J. Guo, H. Hong, G. Chen, S. Shi, Q. Zheng, Y. Zhang, C.P. Theuer, T.E. Barnhart, W. Cai, and S. Gong Image-guided and tumor-targeted drug delivery with radiolabeled unimolecular micelles Biomaterials 34 2013 8323 8332
59. W. Xu, I.A. Siddiqui, M. Nihal, S. Pilla, K. Rosenthal, H. Mukhtar, and S. Gong Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer Biomaterials 34 2013 5244 5253
60. J.M. Chan, J.W. Rhee, C.L. Drum, R.T. Bronson, G. Golomb, R. Langer, and O.C. Farokhzad In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles Proc. Natl. Acad. Sci. U. S. A. 108 2011 19347 19352
61. D.E. Owens 3rd, and N.A. Peppas Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 307 2006 93 102
62. R. Gref, A. Domb, P. Quellec, T. Blunk, R.H. Muller, J.M. Verbavatz, and R. Langer The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres Adv. Drug Deliv. Rev. 16 1995 215 233
63. M.T. Peracchia, E. Fattal, D. Desmaele, M. Besnard, J.P. Noel, J.M. Gomis, M. Appel, J. d'Angelo, and P. Couvreur Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting J. Control. Release 60 1999 121 128
64. G. He, L.L. Ma, J. Pan, and S. Venkatraman ABA and BAB type triblock copolymers of PEG and PLA: a comparative study of drug release properties and "stealth" particle characteristics Int. J. Pharm. 334 2007 48 55
65. M.S. Conte, H.M. Nugent, P. Gaccione, I. Guleria, P. Roy-Chaudhury, and J.H. Lawson Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study J. Vasc. Surg. 50 2009 1359 1368.e1351
66. A.J. Dwivedi, P. Roy-Chaudhury, E.K. Peden, B.J. Browne, E.D. Ladenheim, V.A. Scavo, P.N. Gustafson, M.D. Wong, M. Magill, F. Lindow, A.T. Blair, M.R. Jaff, F.N. Franano, and S.K. Burke Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease J. Vasc. Access 15 2014 376 384
67. R.J. Hye, E.K. Peden, T.P. O'Connor, B.J. Browne, B.S. Dixon, A.S. Schanzer, S.C. Jensik, L.M. Dember, M.R. Jaff, and S.K. Burke Human type I pancreatic elastase treatment of arteriovenous fistulas in patients with chronic kidney disease J. Vasc. Surg. 60 2014 454 461
68. J.H. Alexander, G. Hafley, R.A. Harrington, E.D. Peterson, T.B. Ferguson Jr., T.J. Lorenz, A. Goyal, M. Gibson, M.J. Mack, D. Gennevois, R.M. Califf, and N.T. Kouchoukos Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial JAMA 294 2005 2446 2454
69. M.S. Conte, D.F. Bandyk, A.W. Clowes, G.L. Moneta, L. Seely, T.J. Lorenz, H. Namini, A.D. Hamdan, S.P. Roddy, M. Belkin, S.A. Berceli, R.J. DeMasi, R.H. Samson, and S.S. Berman Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery J. Vasc. Surg. 43 2006 742 751 (discussion 751)
70. M.J. Mann, A.D. Whittemore, M.C. Donaldson, M. Belkin, M.S. Conte, J.F. Polak, E.J. Orav, A. Ehsan, G. Dell'Acqua, and V.J. Dzau Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial Lancet 354 1999 1493 1498